3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neoplasms
1905
Breast Neoplasms
1425
Carcinoma, Non-Small-Cell Lung
1178
Prostatic Neoplasms
740
Colorectal Neoplasms
686
Neoplasm Metastasis
623
Multiple Myeloma
548
Melanoma
529
Ovarian Neoplasms
456
Lung Neoplasms
447
Lymphoma, Non-Hodgkin
385
Lymphoma
374
Recurrence
373
Leukemia, Myeloid, Acute
370
Pancreatic Neoplasms
358
Carcinoma, Renal Cell
339
Carcinoma, Hepatocellular
286
Stomach Neoplasms
281
Leukemia, Lymphocytic, Chronic, B-Cell
268
Lymphoma, Follicular
254
Head and Neck Neoplasms
246
Glioblastoma
220
Leukemia
215
Small Cell Lung Carcinoma
183
Lymphoma, Large B-Cell, Diffuse
183
Squamous Cell Carcinoma of Head and Neck
181
Urinary Bladder Neoplasms
175
Carcinoma
175
Uterine Cervical Neoplasms
174
Advanced Solid Tumors
161
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Malignant Carcinoid Syndrome
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts